GSDME and melanoma: A latest study demonstrated that combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) treatment, a FAD-approved approach for BRAFV600E/K-mutant melanoma, induce GSDME dependent pyroptosis and enhance cytotoxic T-cell infiltration.